Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

Reports Q1 revenue $15.05M, consensus $13.81M. “It has been a remarkable start to 2026 for Intellia,” said John Leonard, Intellia President and Chief Executive Officer. “With lonvo-z, we achieved a historic milestone by presenting the world’s first Phase 3 data for an in vivo gene editing candidate and initiated a rolling BLA submission as we seek to provide a highly differentiated one-time treatment option to people living with HAE. We also recently resumed patient screening for both of our Phase 3 clinical trials in ATTR and strengthened our balance sheet with an underwritten public offering. We look forward to achieving additional important milestones during the remainder of the year.”